Cargando…
Risk factors analysis for hyperuricemic nephropathy among CKD stages 3–4 patients: an epidemiological study of hyperuricemia in CKD stages 3–4 patients in Ningbo, China
Objective: Uric acid (UA) is a risk marker of CKD and SUA level in CKD 3–4 patients closely correlates with hyperuricemic nephropathy (HN) morbidity. This study was designed to evaluate the risk factors for HN in CKD 3–4 patients. Methods: The 461 CKD 3–4 patients were recruited and all patients wer...
Autores principales: | Wu, Yong-Yao, Qiu, Xiao-Hui, Ye, Yun, Gao, Chao, Wu, Fuquan, Xia, Guihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282434/ https://www.ncbi.nlm.nih.gov/pubmed/30489209 http://dx.doi.org/10.1080/0886022X.2018.1487859 |
Ejemplares similares
-
Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients
por: Ghadiani, Mohammad H., et al.
Publicado: (2012) -
Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4
por: Xu, Li, et al.
Publicado: (2022) -
MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant?
por: Delanaye, Pierre, et al.
Publicado: (2010) -
Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study
por: Zhang, Peiyu, et al.
Publicado: (2022) -
The Higher the CKD Stage, the Higher the Psychological Stress in Patients with CKD during COVID-19 Pandemic
por: Lee, Kyung-Mi, et al.
Publicado: (2022)